Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Income from Continuing Operations: 2009-2021

Historic Income from Continuing Operations for Avadel Pharmaceuticals (AVDL) over the last 13 years, with Dec 2021 value amounting to -$85.5 million.

  • Avadel Pharmaceuticals' Income from Continuing Operations fell 894.24% to -$23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$88.2 million, marking a year-over-year decrease of 514.63%. This contributed to the annual value of -$85.5 million for FY2021, which is 1253.58% down from last year.
  • As of FY2021, Avadel Pharmaceuticals' Income from Continuing Operations stood at -$85.5 million, which was down 1,253.58% from -$6.3 million recorded in FY2020.
  • In the past 5 years, Avadel Pharmaceuticals' Income from Continuing Operations ranged from a high of $68.3 million in FY2017 and a low of -$95.3 million during FY2018.
  • In the last 3 years, Avadel Pharmaceuticals' Income from Continuing Operations had a median value of -$76.0 million in 2019 and averaged -$56.0 million.
  • In the last 5 years, Avadel Pharmaceuticals' Income from Continuing Operations spiked by 265.40% in 2017 and then crashed by 1,253.58% in 2021.
  • Over the past 5 years, Avadel Pharmaceuticals' Income from Continuing Operations (Yearly) stood at $68.3 million in 2017, then crashed by 239.60% to -$95.3 million in 2018, then increased by 20.22% to -$76.0 million in 2019, then skyrocketed by 91.69% to -$6.3 million in 2020, then plummeted by 1,253.58% to -$85.5 million in 2021.